Recent Updates
Recently added Catalysts
IRIX Positive Sentiment Score: 60/100

Iridex to Report Second Quarter Financial Results on August 10, 2023

Thursday, July 27, 2023 2 min read
Key Takeaway: Iridex Corporation has announced it will report its financial results for the second quarter of 2023 on August 10, 2023. The release will occur after the market closes, followed by a conference call at 2:00 p.m. PT. The company specializes in laser-based medical devices for treating glaucoma and retinal diseases, showcasing its commitment to advancing ophthalmic health. Interested investors can participate in the call via a live and recorded webcast.

Market Sentiment Analysis

POSITIVE FACTORS

  • Iridex is a leader in innovative ophthalmic laser-based medical products.
  • The upcoming financial report could signal strong growth potential.
  • MicroPulse technology provides effective treatment options for serious eye conditions.

Full Press Release Details

MOUNTAIN VIEW, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023 after the close of trading on Thursday, August 10, 2023.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:
investors@iridex.com

Frequently Asked Questions

When will Iridex release its Q2 2023 financial results?

Iridex will release its Q2 2023 financial results on August 10, 2023.

What time is the Iridex conference call scheduled?

The conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.

How can investors access the Iridex conference call?

Investors can access the conference call via the webcast on Iridex's website.

What conditions does Iridex's technology treat?

Iridex's technology treats glaucoma and diabetic macular edema, among other conditions.

In how many countries are Iridex products available?

Iridex products are available in over 100 countries worldwide.

Tags: IRIX Viatris Investor Conferences Healthcare Iridex Corporation ophthalmic laser products financial results glaucoma treatment
Last updated: Jul 27, 2023